e-Drug3D

2098

QUIZARTINIB

INN
QUIZARTINIB

cas 950769-58-1

CLASS

ANTINEOPLASTIC
TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
TYROSINE KINASE FLT3 INHIBITOR
BIND TO THE ADENOSINE TRIPHOSPHATE (ATP) BINDING DOMAIN

ROUTE (list)

ORAL

ATC code

L01EX11

PK parameters

F 71 PERCENT
Tmax 4 HOUR
VD 275 LITER
Cl 2.23 LITER / HOUR
PPB 99 PERCENT
t1/2 81 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET TYROSINE KINASE FLT3

PDB
4XUF (CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR QUIZARTINIB (AC220))

Download experimental 3D coordinates of P30 with added hydrogens

Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3

Download SDF file

Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]- (ACI)

Formula:
C29H32N6O4S

Calculated chemical properties:

MW 560.68
NB_atoms 40
XLogP 5.86
PSA 99.744
NB_HD 2
NB_HA 10
fsp3 0.34
Lipinski(0=no;1=yes) 0

FDA
NDA 216993 (pdf not found) INN (QUIZARTINIB DIHYDROCHLORIDE) VANFLYTA (DAIICHI SANKYO INC) APPROVAL= AP YEAR= 2023 NEWMOLECULARENTITY